Member Info for The_Paladin

Sincerest apologies ironknut.

I thought otherwise from your previous message. I believe that there could well be a turnaround in this company’s fortunes? The long wait for a meaningful update is daunting, but until we hear otherwise, we are still in the game. ATB.

Manifesto. I am as frustrated as any Synairgen investor. However, until the company has a meaningful update to share, there is nothing to add to the re-iterated information that TipTop09 received this morning.

As for the non essential-information issued on LinkedIn and twitter, the latest being the Synairgen women in science initiative, I view this as a measure of the confidence that the company has in its future success. All IMHO, DYOR etc.

ATB, GLALTHs.

Thank you for sharing this information TipTop09.

Although there is nothing new here, the company cannot divulge more than this at present. I agree that an EGM would not be productive. Richard Marsden could not add to the information that Brooke Clarke continuously re-iterates to investors.

I am as frustrated by the lack of updates as anyone else. However, I remain optimistic for the future. IMHO, Synairgen does not have the demeanour of a failed company. Should this turn out to be the case, I will have badly misjudged the situation.

GLA.

ironknut.

Your post shows that you have not troubled to get your facts correct before posting? Why are you even remotely interested in a small “virtually worthless” company? It always puzzles me when random uninvested people choose to comment on the bulletin board of a company for which they have little if any regard ?

Having glanced at a recent conversation here, I am puzzled by one statement? How could a large pharmaceutical company buy out the shares of a small research company at a differential rate of purchase?

Presumably, they would need to purchase TFG’s shares, and perhaps those of the largest shareholders within the company, before Feb 21? Subsequently, they would seek to stiff the rest of us with a lower offer post Feb 21? Surely underhand malpractice of this description would qualify for close examination by the FCA?

On a more positive note, if they were to put forward an offer of 150 - 200p to all shareholders, they would most likely secure more than 50% of Synairgen without too much difficulty. That would put them in control of the company.

This month may well spring a surprise? Personally, I would prefer a different way forward through an SNG001 trial? I have switched my opinion to the latter. It would undoubtedly bring a better return to shareholders.

GLA.

This advertisement for a significant US role with the company would not have been place without something concrete in place to justify it IMHO? Synairgen have already made huge mistakes with those significant hires while the Sprinter trial was still in progress. They simply cannot afford to make further similar errors.

LTIs have good reason to be optimistic at present. However, until we have the necessary significant update to verify that the company is back on track, we will remain in this year-long hugely depleted limbo. Our patience is now being tested on a daily basis as the first anniversary of the share price catastrophe approaches.

It is high time for Richard Marsden to step up and get the job done. His New Year message, which was an amalgam of snippets from RNSs dating back to last March, coupled with a nebulous “strategy” is far from being good enough. It is necessary for him, and his highly incentivised associates to get the show back on the road. The recent educational initiatives should happen within a thriving company, and not one that should be focusing on fighting hard to get the necessary deals done.

GLA.

JD76. Synairgen has presented plenty of information during the last six months or so. Unfortunately, none of it has had any lasting positive effect on the share price. For this to happen, they need to have in place a route towards the commercialisation of SNG001. If Synairgen are to retain control of SNG001, they will need to negotiate a suitable trial opportunity this year, sooner rather than later - before the cash reserves become too depleted.

I agree that the regular recycling of the same information on twitter and LinkedIn is puzzling? Recently there has been an initiative celebrating female physicians in the USA, and women in Science. I am always in favour of this type of initiative, but as an LTI, I believe that it is high time for Synairgen to move forward positively again. The vague outline of what the company is aiming to achieve has gone on for too long IMHO. A more well defined announcement of Synairgen’s future plans is necessary to retain LTIs’ confidence. GLA.

This is negligible so far today so that any comment from the “resident” short-term seller should be ignored. Anyone who spends their time constantly writing the same disparaging comments about a company on an insignificant bulletin board week-in, week-out must either be in the latter investor category, or else may be suffering from mental health issues IMHO?

One thing for sure. It is one year down the line, and nothing yet has emerged to turn the company’s fortunes around. Every comment from the company is directed towards the US. All LTIs here have indeed shown a good measure of resilience, and it would be pleasing if our patience were rewarded by a significant update in the not too distant future.
GLA.

Practically everything I have read about Synairgen lately indicates that the company’s future plans will be realised in the USA. However, it does feel more as though we are on a “slow boat to China” than pressing ahead at haste.

I am not qualified to judge. My only aspiration here is to get a return of my invested capital. Any profit on my original investment would be greatly appreciated, but not absolutely necessary.

Everything I have read, and based my aspiration on is irrelevant, as things stand. Until we receive that vital piece of news to show that the company has a route towards commercialisation, we will remain in the same situation that has prevailed for 11+ months.

My thanks to all contributors for your positive information sharing. I remain optimistic that it will all lead to something positive.

GLA.

Thank you Denny11,

So, the transactions listed as buys and sells are single transactions. Buys could be incorrectly displayed as sells and vice versa. Each two-way transaction is initially achieved between the buyer/seller and the broker, who is an intermediary entity. The balance in each transaction is achieved at that stage of the process.

Sorted, and your comments are much appreciated.

“It is not at all mysterious in this regard.
Your transaction is not a buy - it is a buy AND a sell, you need both for a trade.”

That makes sense, but why do brokers’ information for each company display “Bought volumes”, and “Sold volumes”, which always differ at all times?

Thank you Spacman for introducing a much needed different perspective on regularly discussed items on this board. There is little point in anyone feeling threatened by what you are postulating.

Synairgen’s derisory trial planning and execution got investors into our current situation. There is little point in dwelling on that. Instead, we should reflect positively on what lies ahead. Should the situation go from bad to worse, so be it. We all knew the risks when we took on this investment. As things turned out, the personnel managing the situation lacked the necessary skills to get the job done.

Unfortunately, this has been a hugely costly mistake for some of us. Ultimately, I have to take full responsibility for my own actions. I took certain risky and ultimately stupid decisions. It is my own actions that have resulted in my current misfortune and not the poor execution of the Sprinter trial.

The lack of any significant updates for nearly a year hasn’t helped matters. It would be useful to see some positive developments soon.

GLA

Axe-Capital.

Many thanks for your reply. I concur with your view, and current outlook for our treatment.

IMHO the reason we are in our current limbo is that the company has yet to identify a route to commercialisation to replace the clear path that was in place prior to the abject failure of the Sprinter trial. Since then, the company has analysed and given feedback about its existing data, presented the Sprinter trial data at several notable USA conferences, produced some educational materials - two podcasts, and a Scientific American led discussion, and published a peer reviewed paper, which effectively draws a line under the Sprinter trial. I previously referred to these actions as "sweating the small stuff". Most of it may be helpful in enabling the company to press forward, but none of it has had any impact whatsoever on how the market currently views the company.

There is little point in dwelling on past failures. Instead I choose to be optimistic regarding future prospects. The company has a concept-led vision for future progress. It will need to secure a trial to prove the concept, initially for a single virus, before we see any upward share price movement. A year ago, investors were singing the praises of Richard Marsden and his team. It is high time for him to press on from the 2022 summary, and nebulous "vision" in his new year statement to investors. A host-directed, agnostic, broad-spectrum antiviral product could have a major impact if it is fully realised. It is time for the Synairgen team to restore investors' confidence in their ability to deliver a suitable trial opportunity, as outlined in the CEO's "vision". The sooner they are able to do that, the better as far as I am concerned. It has been nearly a year without measurable progress, and time to deliver on their repeated message to investors, in various incarnations, since the last AGM.

All the best to you Axe. GLA.

Thank you for your clear explanation Spacman. I am not ruling anything out at this point in time. I agree with Ghia that the company will do whatever is necessary to bring its drug to market. I would, however, question their integrity if investors lost out in a major way, while the company and its personnel thrived as a consequence. The reason we are in this position is because of the poor decisions taken during the Sprinter trial. However, I accept that the situation is as it is and we shall have to wait and see what unfolds? GLA.

The recent Synairgen messages seem to be on a loop and are continuously reintroduced on the above platforms. Is this measure Synairgen specific, or do other companies do the same? I have just received notification of the reissue of the Scientific American round table discussion having received the same a few days ago. I am not questioning the company's judgement on this. As an investor, my aspiration is for the company to achieve the right endpoint for my investment by whatever means.

Axe. You said that you had reinvested in Synairgen a while ago, and you seemed to be optimistic more optimistic about the company's prospects at the time? Did I misread your post? Have you sold, and changed your mind since then? It seems that way. I agree that Lloyds Banking Group is a sound investment, even at the current price. Should I achieve a suitable exit point from Synairgen, I will buy some for my dividends portfolio. Despite what you and others say about Synairgen, I believe that a recovery may well be on the cards, but due to current uncertainties, I cannot predict when? Time will tell if I am right or wrong? For the time being, investors can but wait and see. GLA.

Thank you Fazer1.

I am replying under Elsol's positive header rather than the dispiriting title that was introduced yesterday to promote a negative narrative. I couldn't access the article from the link, but it sounds as though it is yet another repeated piece of news. It is a positive statement, and well worth recycling as it maintains an awareness of SNG001, and its potential.

My view, is that the immediate future may will lie with a STRIVE trial invitation with future pandemic preparedness at the forefront of the NIH's agenda. My opinion only, DYOR etc. I was catastrophically wrong in my assessment last February, as were Synairgen's Sprinter trial team, and most LTIs, and I may have misjudged the current situation?

As I see it, Strive would give us a foot in the door. I agree that Synairgen would have no control of the process, but the market would be presented with a process that could lead to future commercialisation, and might upwardly re-rate the share price as a result? Moreover, the interest of a major pharmaceutical company could be raised as a consequence?

LTIs like myself, are currently dispirited by Synairgen's discernible lack of progress in accessing a trial? The comms amount to recycling low-level information that has been presented before, some of it on multiple occasions. Doc.Dan's thoughts yesterday mirrored my own, in that for a year, the company has merely brought previous projects to a conclusion. External consultants have been used for this, and we have no idea of the contribution made by the in-house team of experts that Richard Marsden hired in anticipation of Sprinter success? The hiring has continued in recent months. News of a secured trial opportunity is needed at this point in time. The "strategy" that has been repeated for six months, and included in the CEO's nebulous new year's statement is no longer enough. Investors need to learn if any real progress has been made towards realising Synairgen's lofty aspirations?

GLA

Good post Doc83. Your first paragraph sums up our situation. We are now approaching mid winter. A previous vague communication from Richard Marsden led investors to believe that something would have happened by now?

Everything is in good shape, and ready for an appropriate deal to relaunch the Synairgen rocket. As time goes on, I am thinking T/O as opposed to trial. I sincerely hope that I am proven to be wrong. I have been invested since August 2020 , always adding, never selling. My belief in SNG001 remains in place, although the apparent inaction with regard to finalising a trial opportunity is a cause for concern.

We do need a proper update, not the same rinse and repeat that we have been receiving for several months. I am invested in a product, not an innovative concept, which is at the forefront of most of the company’s actions. The concept will fall into place naturally once the trialling of the product is done.

GLA

Thank you Sparky for doing that, and for keeping us in the loop. If the company was unaware of investors’ concerns before, your call will have changed that. One positive development will change everything. For the time being, we are in the dark about Synairgen’s future plans.

All the best to you. GLA.

I was wrong in my earlier assessment. On removing the filter, and reading Andybe4’s recent messages, I find that he confirms to the accepted definition of a narcissistic troll. The superior tone, the condescension towards others, and the invitation for dialogue at a personal level seems to feature in these individuals’ messages. I stopped my visits to another SNG board to avoid the regular taunting from another troll, who operates in a similar way. I am not qualified to comment about mental health issues, but these individuals are very different to anyone in my acquaintance.

One important point IMHO. I tend to filter trolls most of the time, but occasionally read their messages. When responding to trolls, it might be a good idea to change their header. Andybe4’s previous header was there to disrupt. All responses to his message while maintaining his header perpetrated his intention to disrupt the board.

I remain optimistic for positive news, which will obliterate the presence of trolls for good. GLA.

I hope that you are right Sharedealer2019. I know very little about the mechanism involved, and your comment is plausible.

I have been patiently waiting for some sign of share price recovery for a considerable time. My comments earlier today are a reflection of my frustration with the continued lack of substantial news, and do not reflect my personal view that the share price will eventually turn around and recover.

ATB and GLA.